Digitalis pharmacokinetics and metabolism
- PMID: 1092160
- DOI: 10.1016/0002-9343(75)90116-3
Digitalis pharmacokinetics and metabolism
Abstract
The pharmacokinetics of the cardiac glycofides have been elucidated as a result of the development of assays of sufficient sensitivity to measure the concentration of digitalis compounds in biological fluids. Digoxin can accumulate in the body without the administration of a loading dose, and a steady state blood concentration will be reached in 5 to 7 days. Digitoxin requires 35 days to accumulate to a plateau. If a loading dose of digoxin is used, it should be approximately three times the estimated daily maintenance dose. Factors that determine the selection of the appropriate maintenance dose of digoxin include renal function and lean body mass. Digitoxin is less dependent on renal function for its elimination than is digoxin. Knowledge of the pharmacokinetics of digitalis preparations is useful in determining how to change from one cardiac glycoside to another, each with different half-lives. One should wait 3 days before starting digoxin therapy when changing from maintenance digitoxin to digoxin (assuming normal renal function). The pharmacokinetics of changing from ouabain to digoxin without loss of digitalis effect are described. The metabolism of the commonly used digitalis preparations are summarized.
Similar articles
-
Digitalis therapy in renal failure with special regard to digitoxin.Int J Clin Pharmacol Ther Toxicol. 1981 Apr;19(4):175-84. Int J Clin Pharmacol Ther Toxicol. 1981. PMID: 7021432 Review.
-
Digitalis pharmacokinetics and therapy with respect to impaired renal function.Klin Wochenschr. 1977 Jan 1;55(1):1-11. doi: 10.1007/BF01469777. Klin Wochenschr. 1977. PMID: 319291 Review.
-
Clinical Use of Digitalis: A State of the Art Review.Am J Cardiovasc Drugs. 2018 Dec;18(6):427-440. doi: 10.1007/s40256-018-0292-1. Am J Cardiovasc Drugs. 2018. PMID: 30066080
-
Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs.Clin Exp Pharmacol Physiol. 1975 Nov-Dec;2(6):489-502. doi: 10.1111/j.1440-1681.1975.tb01854.x. Clin Exp Pharmacol Physiol. 1975. PMID: 1236603
-
Congestive heart failure.J Am Pharm Assoc. 1974 Jul;14(7):362-75. J Am Pharm Assoc. 1974. PMID: 4604267 Review. No abstract available.
Cited by
-
Serum digoxin test in perspective.Can Med Assoc J. 1977 Nov 5;117(9):994-6. Can Med Assoc J. 1977. PMID: 912635 Free PMC article. No abstract available.
-
The appropriate use of serum digoxin assay.Can Fam Physician. 1977 Oct;23:107-13. Can Fam Physician. 1977. PMID: 21304851 Free PMC article.
-
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Clin Pharmacokinet. 2010 Apr;49(4):223-37. doi: 10.2165/11318000-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20214407 Review.
-
Digoxin intoxication: An old enemy in modern era.J Geriatr Cardiol. 2012 Sep;9(3):237-42. doi: 10.3724/SP.J.1263.2012.01101. J Geriatr Cardiol. 2012. PMID: 23097652 Free PMC article.
-
Predicting compliance with a regimen of digoxin therapy in family practice.Can Med Assoc J. 1980 Jul 19;123(2):119-22. Can Med Assoc J. 1980. PMID: 7260749 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
